Find a Doctor

Dr. Breelyn Ann Wilky

University Physicians, Incorporated
Oncology, Hematology, Internal Medicine
Female
Practicing approx. 15 years

Bio


Breelyn Wilky is an Oncologist and an Internal Medicine specialist in Aurora, Colorado. Dr. Wilky is a global expert in Rhabdoid Tumor Predisposition Syndrome. She has been an author on 42 peer reviewed articles and participated in 6 clinical trials in the past 15 years. In particular, she has been an author on 1 peer reviewed article regarding Rhabdoid Tumor Predisposition Syndrome. She is licensed to treat patients in FL and CO.

Contact

12605 E 16th Ave
Uchealth Anschutz Medical Campus
Aurora, CO 80045, US

Latest Advances


  • Condition: Synovial Sarcoma (SS)
  • Journal: Journal for immunotherapy of cancer
  • Treatment Used: Adoptive Transfer of NY-ESO-1 SPEAR T Cells
  • Number of Patients: 42
  • Published —
These studies addressed the immunological mechanisms of response and resistance in patients with synovial sarcoma (SS) treated with NY-ESO-1 SPEAR T-cells.
  • Condition: Angiosarcoma
  • Journal: Journal for immunotherapy of cancer
  • Treatment Used: Immune Checkpoint Inhibitors
  • Number of Patients: 7
  • Published —
This study analyzed patients with locally advanced or metastatic angiosarcoma, who were treated with checkpoint inhibitors.
  • Condition: Advanced sarcomas including alveolar soft-part sarcoma
  • Journal: The Lancet. Oncology
  • Treatment Used: Axitinib plus pembrolizumab
  • Number of Patients: 36
  • Published —
The study researched the effects of Axitinib plus Pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma.

Clinical Trials


Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 55
  • Start Date: February 2021
A Phase 2 Study Examining AGEN2034 as a Single-Agent and in Combination With AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 105
  • Start Date: January 5, 2021
A Randomized Phase II Trial of Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Genetic
  • Participants: 90
  • Start Date: July 24, 2019
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Contact

12605 E 16th Ave
Uchealth Anschutz Medical Campus
Aurora, CO 80045, US

Affiliations

  • University Of Colorado Hospital Authority
  • Uch-Memorial Health System
  • Uchealth Highlands Ranch Hospital

Credentials

  • Graduate InstitutionRutgers R W Johnson Medical School (Cam/new Bruns/pisc)
    2006
  • Licenses
    Internal Medicine in FL
  • Board Certifications
    Medical Oncology
    Internal Medicine

Insurance

Contact them to find out if they accept your insurance plan.